Skip to content
HowShorted

Terns Pharmaceuticals, Inc. short interest in 2024

In 2024, Terns Pharmaceuticals, Inc.'s disclosed short interest ran from 7.11% of shares outstanding on 12 Jan 2024 to 8.68% on 31 Dec 2024, a change of +1.57 percentage points. The year's high was 8.68% on 31 Dec 2024 and its low 2.56% on 15 Aug 2024, averaging 5.62% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.52 days on 31 Jan 2024. Full history: Terns Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Terns Pharmaceuticals, Inc. in 2024

2024 in figures

Start of year
7.11% (12 Jan 2024)
End of year
8.68% (31 Dec 2024)
Change
+1.57 pp
High
8.68% (31 Dec 2024)
Low
2.56% (15 Aug 2024)
Average
5.62%
Highest days to cover
7.52 (31 Jan 2024)
SEC filings marked
8

Every report in 2024

Terns Pharmaceuticals, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20247.11%5.85
31 Jan 20246.86%7.52
15 Feb 20247.06%7.26
29 Feb 20247.09%5.95
15 Mar 20246.54%2.8210-K filed, results (8-K)
28 Mar 20246.95%5.52
15 Apr 20246.80%4.05
30 Apr 20246.94%6.72
15 May 20243.46%2.6810-Q filed, results (8-K)
31 May 20243.29%2.69
14 Jun 20243.55%1.53
28 Jun 20244.15%1.63
15 Jul 20243.08%1.55
31 Jul 20243.76%2.30
15 Aug 20242.56%1.9710-Q filed, results (8-K)
30 Aug 20243.77%2.61
13 Sep 20245.35%1.00
30 Sep 20246.98%2.79
15 Oct 20246.18%3.31
31 Oct 20246.45%3.43
15 Nov 20244.68%3.3510-Q filed, results (8-K)
29 Nov 20246.34%3.48
13 Dec 20247.30%3.03
31 Dec 20248.68%3.67

See also: Terns Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.